← العودة إلى الصفحة الرئيسية
آسيا · الأسواق الإقليمية · Vietnam Investment Review

Yicura BioMed completes first closing of Series B financing

نشره Vietnam Investment Review · فيتنام منذ 17 س
Yicura BioMed completes first closing of Series B financing
Yicura BioMed completes first closing of Series B financing · Vietnam Investment Review

ملخص مفصل

Clinical-stage immunotherapy firm Yicura BioMed completed the first closing of its Series B funding round led by Gobi Partners on 13 November 2026 to advance its ICVAX HIV product.

HONG KONG SAR – Media OutReach Newswire – 13 November 2026 – Yicura BioMed ("Yicura"), a clinical-stage immunotherapy company based in the Hong Kong Science Park developing medicines for infectious diseases, cancers, and inflammatory diseases, is pleased to announce today the first closing of its Series B financing led by Gobi Partners, with participation from a number of strategic investors from Wuxi and institutional investors from Hong Kong. Their participation reflects shared confidence in Yicura's clinical development path.

The issuer is solely responsible for the content of this announcement.

مطلع المقال، مقتطف من Vietnam Investment Review. لقراءة المقال كاملًا، افتحه على موقع الناشر.

اقرأ المقال كاملًا على Vietnam Investment Review سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (vir.com.vn)

يستحق القراءة أيضًا